↓ Skip to main content

A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Overview of attention for article published in BMC Cancer, July 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
5 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
19 Mendeley